Log in
Enquire now
‌

GEL4MED, INC. SBIR Phase I Award, April 2019

A SBIR Phase I contract was awarded to Gel4Med, Inc. in April, 2019 for $348,852.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health.

OverviewStructured DataIssuesContributors

Contents

sbir.gov/node/1682021
Is a
SBIR/STTR Awards
SBIR/STTR Awards

SBIR/STTR Award attributes

SBIR/STTR Award Recipient
‌
Gel4Med, Inc.
0
Government Agency
0
Government Branch
National Institutes of Health
National Institutes of Health
0
Award Type
SBIR0
Contract Number (US Government)
1R44GM133305-010
Award Phase
Phase I0
Award Amount (USD)
348,8520
Date Awarded
April 1, 2019
0
End Date
March 31, 2020
0
Abstract

OverviewThis Fast track project aims to test the feasibility of a self assembly peptide hydrogel for the treatment of woundsWound care is currently an expensivemultistep process in which wounds are treated with sequential products toremove pathogens with antibioticspromote a healthy cellular environment through hydrogel applicationandclose the wound with skin substitutesThusthe proposed product G Derm is capable of simultaneously removing drug resistant pathogens through biophysical disruption of bacterial membraneswhile promoting host tissue regeneration without added antibiotics or biologicsThis product can be used in inpatient and outpatient wound care clinics to heal patients infected with drug resistant bacteriaand to reduce theamputations performed each year in the US due to chronic woundsKey wordstissue regenerationinfectionswound healingbiomaterialsantimicrobial Areas of applicationtissue regeneration and repairwound healinginfections Subtopic nameBiomedicalBMTechnologies Intellectual MeritThis Fast track proposal will generatekenabling data demonstrating safety and efficacy of G Derm as an antimicrobial cell scaffolding matrix that is simultaneously toxic to antibioticresistant bacterial strainswhile remaining conducive to tissue regenerationThe current product uses a charge based mechanism to lyse bacterial membranes upon contact and has a porous structure to promote cellular infiltration and cell attachmentBroader ImpactThe broader impact of this Fast track proposal would be the development of a novel antimicrobial mechanism that can eliminate even drug resistant bacterial strains from infected woundsAccording to the Centers for Disease Control and Prevention Reportantibiotic resistant bacteria will cause serious infections inmillion Americans each yearresulting in an estimateddeaths annuallyOur ability to fight antibiotic resistant bacteria is diminishingand the pipeline of new potential antibiotic drugs is growing leanOnlynew antibiotics have received FDA approval sinceof which onlyof these incorporated novel mechanisms of actionHencethe proposed product offers the unprecedented combination of simultaneous bacterial elimination while promoting tisue regenerationAs the antibacterial mechanism is biophysicalbacteria are unlikely to develop resistance to this product Project Narrative The proposed product G Derm is a flowableantimicrobial skin scaffolding matrix that promotes infection free healing of woundsThis product is designed to incorporate three major benefits in a single materialibroad spectrum antimicrobial activityiitissue scaffolding matrixand iiiflowable properties to fill wounds of any sizeshape and depthThis product is easy to apply and has the potential to mitigatemillion infections anddeaths associated with poor wound closure and antibiotic annually

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like GEL4MED, INC. SBIR Phase I Award, April 2019

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.